Phenylethylmalonamide Serum Levels in Patients Treated with Primidone and the Effects of Other Antiepileptic Drugs
- 1 June 1986
- journal article
- research article
- Published by Wolters Kluwer Health in Therapeutic Drug Monitoring
- Vol. 8 (2) , 161-165
- https://doi.org/10.1097/00007691-198606000-00006
Abstract
Data are presented for the serum levels of 2-ethyl-2-phenylmalonamide (PEMA) in patients receiving anticonvulsant medication. Statistical analysis of these data indicates that the serum level of PEMA, which is a metabolite of primidone, is affected not only by the dose of primidone but also by the serum levels of other prescribed anticonvulsant drugs. In particular phenobarbitone is shown to be a major perturbation upon the PEMA serum level.This publication has 2 references indexed in Scilit:
- Pharmacokinetics of Phenylethylmalonamide (PEMA) in Normal Subjects and in Patients Treated with Antiepileptic DrugsEpilepsia, 1982
- Monitoring 2-ethyl-2-phenylmalonamide in serum by gas-liquid chromatography: application to retrospective study in epilepsy patients dosed with primidone.Clinical Chemistry, 1980